drugset
drugset / Trial / NCT03205176

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176 ↗

Phase 1 Completed 49 enrolled AstraZeneca
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

Timeline

Start
2017-06-30
Primary completion
2021-03-01
Completion
2021-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5153 Small molecule — Oral
Subject Olaparib Small molecule 300 mg Oral

Indications

breast cancer lymphoma malignant pancreatic neoplasm ovarian cancer prostate cancer